Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Vaccine|September 24, 2013
Post-authorization safety surveillance of a liquid pentavalent vaccine in Guatemalan childrenEdwin J Asturias, Ingrid L Contreras-Roldan, Malathi Ram, et al.
The Lancet. Infectious Diseases|November 11, 2017
Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled studyXavier Sáez-Llorens, Vianney Tricou, Delia Yu, et al.
Revista Panamericana De Salud Publica = Pan American Journal of Public Health|June 16, 2021
Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico CityShibadas Biswal, Jorge Fernando Mendez Galvan, Mercedes Macias Parra, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 12, 2024
Immunogenicity, Safety, and Efficacy of a Tetravalent Dengue Vaccine in Children and Adolescents: An Analysis by Age GroupCharissa Borja-Tabora, LakKumar Fernando, Eduardo Lopez Medina, et al.
Vaccine|December 18, 2019
Safety and immunogenicity of a single dose of a tetravalent dengue vaccine with two different serotype-2 potencies in adults in Singapore: A phase 2, double-blind, randomised, controlled trialVianney Tricou, Jenny G Low, Helen M Oh, et al.
Lancet (London, England)|March 21, 2020
Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trialVianney Tricou, Xavier Sáez-Llorens, Delia Yu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 8, 2024
Impact of Point-of-Care Birth Test-and-Treat on Clinical Outcomes Among Infants With HIV: A Cluster-Randomized Trial in Mozambique and TanzaniaIlesh V Jani, Issa Sabi, Kira Elsbernd, et al.
The New England Journal of Medicine|November 7, 2019
Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and AdolescentsShibadas Biswal, Humberto Reynales, Xavier Saez-Llorens, et al.
Lancet (London, England)|March 21, 2020
Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trialShibadas Biswal, Charissa Borja-Tabora, Luis Martinez Vargas, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 4, 2021
Three-year Efficacy and Safety of Takeda's Dengue Vaccine Candidate (TAK-003)Luis Rivera, Shibadas Biswal, Xavier Sáez-Llorens, et al.
Pageof 3